Investors

 

Experience cutting edge cancer treatments with Isoray.

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

 

Investor Resources

Governance

Research Analyst Coverage

Ascendiant Capital Markets
Edward Woo

Dawson James Securities Inc.
Jason Kolbert

H.C. Wainwright & Co.
Swayampakula Ramakanth, Ph.D.

Investor News Alerts

Use the button below to email us and receive the latest investor focused news from Isoray.

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Our Management Team

 

Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results

Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy RICHLAND, WASHINGTON – September 24, 2019 – Isoray, Inc....

A Decade of Data Shows the Value of Isoray’s Cesium-131 As Prostate Cancer Internal Radiation Therapy Treatment

Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2% Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to...

Isoray To Announce Fourth Quarter and Year End 2019 Financial Results on September 24, 2019

Conference Call is Tuesday, September 24, 2019, at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 12, 2019 – Isoray, Inc. (NYSE...

Isoray To Spotlight Cesium-131 Advances in Treating Hard to Treat Cancers at the American Society for Radiation Oncology Annual Meeting

RICHLAND, WASHINGTON – September 10, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy...

Don’t miss us and come discover the Power of Blu™ at ASTRO 2019

At Isoray, we recognize the value of industry conferences, specifically when it comes to continuing your education, staying up-to-date with the latest research, and networking with industry colleagues. Our team is looking forward to once again having the opportunity to join the radiation oncologist community at the ASTRO Annual Meeting to discuss the most recent developments in cancer treatment.